Shedding light on immunotherapy for cancer.
作者信息
Rosenberg Steven A
机构信息
National Cancer Institute, Bethesda, Md, USA.
出版信息
N Engl J Med. 2004 Apr 1;350(14):1461-3. doi: 10.1056/NEJMcibr045001.
Abstract
摘要
相似文献
1
Shedding light on immunotherapy for cancer.揭示癌症免疫疗法
N Engl J Med. 2004 Apr 1;350(14):1461-3. doi: 10.1056/NEJMcibr045001.
2
Priming of naive T cells inside tumors leads to eradication of established tumors.肿瘤内初始T细胞的启动可导致已形成肿瘤的根除。
Nat Immunol. 2004 Feb;5(2):141-9. doi: 10.1038/ni1029. Epub 2004 Jan 4.
3
LIGHTing the way for tumor immunity.照亮肿瘤免疫之路。
Nat Immunol. 2004 Feb;5(2):123-4. doi: 10.1038/ni0204-123.
4
LIGHT-HVEM signaling and the regulation of T cell-mediated immunity.LIGHT-HVEM信号传导与T细胞介导的免疫调节。
Cytokine Growth Factor Rev. 2003 Jun-Aug;14(3-4):289-96. doi: 10.1016/s1359-6101(03)00031-5.
5
The TNF superfamily members LIGHT and CD154 (CD40 ligand) costimulate induction of dendritic cell maturation and elicit specific CTL activity.肿瘤坏死因子超家族成员LIGHT和CD154（CD40配体）共同刺激树突状细胞成熟的诱导并引发特异性CTL活性。
J Immunol. 2001 Sep 1;167(5):2479-86. doi: 10.4049/jimmunol.167.5.2479.
6
Introduction: Cancer Immunology Special Issue-Immunotherapy.引言：癌症免疫学特刊——免疫疗法。
Int Immunol. 2016 Jul;28(7):317. doi: 10.1093/intimm/dxw028. Epub 2016 Jun 15.
7
STING signaling: a key to therapeutic tumor immunity.干扰素基因刺激蛋白信号传导：肿瘤免疫治疗的关键
Immunotherapy. 2018 Jul;10(9):729-731. doi: 10.2217/imt-2018-0064.
8
Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway.通过LIGHT共刺激途径对肿瘤及移植物抗宿主病模型中T细胞介导的免疫进行调节。
Nat Med. 2000 Mar;6(3):283-9. doi: 10.1038/73136.
9
The role of LIGHT in T cell-mediated immunity.LIGHT在T细胞介导的免疫中的作用。
Immunol Res. 2004;30(2):201-14. doi: 10.1385/IR:30:2:201.
10
APRIL and BAFF connect autoimmunity and cancer.增殖诱导配体（APRIL）和B细胞激活因子（BAFF）与自身免疫和癌症相关。
J Exp Med. 2000 Dec 4;192(11):F35-8. doi: 10.1084/jem.192.11.f35.
引用本文的文献
1
Novel fusion superkine, , enhances immunotherapy of brain cancer.新型融合超细胞因子 增强脑癌免疫治疗效果
J Immunother Cancer. 2025 Jun 22;13(6):e011198. doi: 10.1136/jitc-2024-011198.
2
Hacking the Immune Response to Solid Tumors: Harnessing the Anti-Cancer Capacities of Oncolytic Bacteria.破解实体瘤的免疫反应：利用溶瘤细菌的抗癌能力
Pharmaceutics. 2023 Jul 21;15(7):2004. doi: 10.3390/pharmaceutics15072004.
3
Novel paradigm for immunotherapy of ovarian cancer by engaging prophylactic immunity against hepatitis B virus.通过激发针对乙型肝炎病毒的预防性免疫来进行卵巢癌免疫治疗的新范式。
Clin Transl Med. 2016 Dec;5(1):44. doi: 10.1186/s40169-016-0125-2. Epub 2016 Nov 30.
4
Novel paradigm for immunotherapy of breast cancer by engaging prophylactic immunity against hepatitis B.通过激发针对乙型肝炎的预防性免疫来进行乳腺癌免疫治疗的新范式。
Clin Transl Med. 2016 Dec;5(1):32. doi: 10.1186/s40169-016-0111-8. Epub 2016 Aug 18.
5
Immunotherapy for head and neck cancer: latest developments and clinical potential.头颈部癌症的免疫疗法：最新进展与临床潜力
Ther Adv Med Oncol. 2016 May;8(3):168-75. doi: 10.1177/1758834016631529. Epub 2016 Feb 16.
6
Increased NY-ESO-1 expression and reduced infiltrating CD3+ T cells in cutaneous melanoma.皮肤黑色素瘤中 NY-ESO-1 表达增加和浸润性 CD3+ T 细胞减少。
J Immunol Res. 2015;2015:761378. doi: 10.1155/2015/761378. Epub 2015 Apr 14.
7
Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma.使用伊匹单抗抑制CTLA-4治疗转移性黑色素瘤后出现的类伏格特-小柳-原田综合征
J Immunother. 2015 Feb-Mar;38(2):80-4. doi: 10.1097/CJI.0000000000000066.
8
Cellular and molecular chaperone fusion vaccines: targeting resistant cancer cell populations.细胞和分子伴侣融合疫苗：针对耐药癌细胞群体。
Int J Hyperthermia. 2013 Aug;29(5):376-9. doi: 10.3109/02656736.2013.792126. Epub 2013 May 17.
9
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104).Ⅱ期临床试验研究法尼基转移酶抑制剂 R115777 治疗晚期黑色素瘤（CALGB 500104）。
J Transl Med. 2012 Dec 10;10:246. doi: 10.1186/1479-5876-10-246.
10
Irradiation of donor mononuclear cells for treatment of chemorefractory metastatic solid cancers: a community-based immune transplant pilot study.供者单核细胞照射治疗化疗耐药转移性实体瘤：一项社区为基础的免疫移植初步研究。
Cancer Res Treat. 2012 Jun;44(2):133-41. doi: 10.4143/crt.2012.44.2.133. Epub 2012 Jun 30.
本文引用的文献
1
Priming of naive T cells inside tumors leads to eradication of established tumors.肿瘤内初始T细胞的启动可导致已形成肿瘤的根除。
Nat Immunol. 2004 Feb;5(2):141-9. doi: 10.1038/ni1029. Epub 2004 Jan 4.
2
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.自身反应性CD8 + T细胞功能耐受状态逆转后的肿瘤消退和自身免疫。
J Exp Med. 2003 Aug 18;198(4):569-80. doi: 10.1084/jem.20030590.
3
Natural selection of tumor variants in the generation of "tumor escape" phenotypes.肿瘤逃逸表型产生过程中肿瘤变体的自然选择。
Nat Immunol. 2002 Nov;3(11):999-1005. doi: 10.1038/ni1102-999.
4
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.抗肿瘤淋巴细胞克隆性再增殖后患者的癌症消退与自身免疫
Science. 2002 Oct 25;298(5594):850-4. doi: 10.1126/science.1076514. Epub 2002 Sep 19.
5
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.一种用于治疗转移性黑色素瘤患者的合成肽疫苗的免疫学和治疗学评估
Nat Med. 1998 Mar;4(3):321-7. doi: 10.1038/nm0398-321.
Zotero 插件